The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
暂无分享,去创建一个
Xiang Song | G. Tang | Jieting Niu | Mingming Ren | Fanyi Kong | Zhen Sun | Yanguang Li
[1] Wenhui Tao,et al. Circular RNA circCPA4 promotes tumorigenesis by regulating miR‐214‐3p/TGIF2 in lung cancer , 2021, Thoracic cancer.
[2] Shanfeng Zhang,et al. Blocking circ-SCMH1 (hsa_circ_0011946) suppresses acquired DDP resistance of oral squamous cell carcinoma (OSCC) cells both in vitro and in vivo by sponging miR-338-3p and regulating LIN28B , 2021, Cancer cell international.
[3] Junguang Jiang,et al. Circ_0006988 promotes the proliferation, metastasis and angiogenesis of non-small cell lung cancer cells by modulating miR-491-5p/MAP3K3 axis , 2021, Cell cycle.
[4] Yang Cao,et al. CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway , 2021, OncoTargets and therapy.
[5] Rusong Yang,et al. Alginic acid inhibits non-small cell lung cancer-induced angiogenesis via activating miR-506 expression , 2021, Journal of Natural Medicines.
[6] Ho-Yyoung Lee,et al. Mechanisms of resistance to chemotherapy in non-small cell lung cancer , 2021, Archives of Pharmacal Research.
[7] Zhu Jin,et al. Depletion of circ-BIRC6, a circular RNA, suppresses non-small cell lung cancer progression by targeting miR-4491. , 2020, Bioscience trends.
[8] Ke Wang,et al. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells , 2020, Molecular and Cellular Biochemistry.
[9] Y. Ling,et al. CircRNA DONSON contributes to cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis , 2020, Cancer Cell International.
[10] Mu Zhang,et al. The circular RNA 001971/miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA , 2020, Journal of experimental & clinical cancer research : CR.
[11] I. Wakabayashi,et al. HDGF enhances VEGF-dependent angiogenesis and FGF-2 is a VEGF-independent angiogenic factor in non-small cell lung cancer , 2020, Oncology reports.
[12] R. Guleria,et al. Differential expression of circulating serum miR-1249-3p, miR-3195, and miR-3692-3p in non-small cell lung cancer , 2020, Human Cell.
[13] N. Hanna,et al. The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future. , 2020, Clinical lung cancer.
[14] Xinwei Han,et al. Circular RNA HIPK3 induces cell proliferation and inhibits apoptosis in non-small cell lung cancer through sponging miR-149 , 2020, Cancer biology & therapy.
[15] Jørgen Kjems,et al. The biogenesis, biology and characterization of circular RNAs , 2019, Nature Reviews Genetics.
[16] Yolan J. Reckman,et al. Circular RNAs open a new chapter in cardiovascular biology , 2019, Nature Reviews Cardiology.
[17] Minhua Wu,et al. Long non-coding RNA MIF-AS1 promotes breast cancer cell proliferation, migration and EMT process through regulating miR-1249-3p/HOXB8 axis. , 2019, Pathology, research and practice.
[18] Zhaocai Zhou,et al. Structure and Degradation of Circular RNAs Regulate PKR Activation in Innate Immunity , 2019, Cell.
[19] T. Orlowski,et al. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients , 2019, Cellular and Molecular Life Sciences.
[20] Yu-qin Pan,et al. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2 , 2019, Cell Death & Disease.
[21] Yue Zhang,et al. MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A , 2018, Cell Death & Disease.
[22] Rafael Rosell,et al. Genetics and biomarkers in personalisation of lung cancer treatment , 2013, The Lancet.
[23] Michael M Gottesman,et al. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.
[24] D. Cheresh,et al. Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.
[25] Quynh-Thu Le,et al. Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .
[26] I. Judson,et al. New Developments and Approaches in the Platinum Arena , 2012, Drugs.